Information Manufacturing Patients Specialization 
The Medical Futurist
JUNE 17, 2025
Just like in the case of other medical specialties , disruptive innovations will have a huge impact on how dentistry will be practiced and how patients will take care of themselves in the future. For patients, it promises more accurate care and better outcomes. How about having a teledentist consultation?
FDA Law Blog
APRIL 25, 2023
Shapiro — Does your firm manufacture a “cyber device”? The primary vehicle for FDA to request cybersecurity information in premarket submissions has been guidance documents. Congress has given FDA the authority to require device manufacturers to provide cybersecurity information in their premarket submissions for a “cyber device.”
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
The Medical Futurist
JUNE 21, 2025
Compared to that, our hearing only processes 11 percent of information, while smell 3.5 In 2015, surgeons in Manchester, UK have performed the first bionic eye implant for an AMD patient using Second Sight’s innovation. percent, touch 1.5 percent and taste 1 percent. Don’t you think that’s possible? Renowned scholars, L.D.
FDA Law Blog
MAY 8, 2023
The discussion paper described a PCCP as including (1) the types of anticipated modifications (SaMD Pre-Specifications or SPS) based on the retraining and model update strategy and (2) the associated methodology (Algorithm Change Protocol or ACP) being used to implement those changes in a controlled manner to manage patient risks.
CDOCS
FEBRUARY 14, 2025
These files can be stored alongside other patient records, shared with colleagues, or included in lab orders for streamlined collaboration.& </strong> now allows users to upload bridge case designs to DS Core, enabling centralized management of end-to-end manufacturing tasks. .&
FDA Law Blog
MAY 19, 2023
In this blog we examine the Special Controls put in place to mitigate false results, incorrect interpretation of results, and incorrect operation of the device. The Special Controls are silent on what would constitute appropriate levels of evidence necessary to satisfy this criterion. analytical, clinical and stability).
FDA Law Blog
OCTOBER 2, 2024
On the other hand, the Draft Guidance states that a significant change to the design of a printed circuit board (PCB) in a multi-parameter physiological patient monitor, with arrhythmia detection alarms for use in a hospital environment, would not be appropriate for inclusion in a PCCP. Draft Guidance at 4. Draft Guidance at 34.
Expert insights. Personalized for you.
126 
Let's personalize your content